The French biotech firm Cellectis won U.S. regulatory approval to run an early clinical trial using its gene edited cell therapy product UCART123 for blood cancers.

Novartis’ experimental CAR-T therapy CLT019 sent 82 percent of patients’ blood cancer into remission, according to interim data presented at the American Society of Hematology.

Juno Therapeutics Inc. said two more patients had died after suffering brain swelling during a trial of its experimental genetically engineered leukemia drug.

Christian Homsy, the CEO of Celyad, blasted Cellectis and its chief executive over a dispute regarding a patent claim for a CAR-T treatment.

Study shows Juno’s JCAR014 CAR-T therapy for non-Hodgkin lymphoma was highly effective in patients who had undergone chemotherapy called lymphodepletion.

Novartis AG is dissolving its Cell and Gene Therapy Unit, according to Endpoints News, citing a note sent to 400 employees by division president Usman Azam.

Juno Therapeutics faces a class action lawsuit alleging the company violated federal securities law pertaining to a patient death in a Phase II trial of its lead drug.

Boston’s Ziopharm Oncology released information that a patient receiving gene therapy into a brain tumor died from an intracranial hemorrhage.

U.S. drugmaker Pfizer and France’s Servier have snapped up rights to a promising cell therapy developed by French biotech firm Cellectis to fight blood cancers. The so-called CAR T cell technology used by Cellectis involves reprogramming immune system cells to hunt out cancer. The “off-the-shelf” approach recently proved very successful in the case of a […]

Some leukemia patients who had exhausted other treatment options have no trace of the disease more than four years after being treated with an experimental type of therapy called CAR T cells in a small pilot study at the University of Pennsylvania. The 14-patient study, which began in the summer of 2010, enrolled patients who […]